Stock AVBP ARRIVENT BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News ArriVent BioPharma, Inc.

Equities

AVBP

US04272N1028

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-14 EDT 		5-day change 1st Jan Change
18.7 USD -0.69% Intraday chart for ArriVent BioPharma, Inc. +0.81% 0.00%
06-05 ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment MT
06-05 Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment
MT
Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates
MT
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
AQ
Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Enters into Research and Collaboration Agreement with Arrivent Biopharma, Inc
CI
ArriVent Appoints John Hohneker, M.D., to its Board of Directors
AQ
ArriVent BioPharma, Inc. Appoints John Hohneker as Board of Directors
CI
ArriVent BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
ArriVent BioPharma Reports First Quarter 2024 Financial Results
AQ
HC Wainwright Initiates ArriVent BioPharma With Buy Rating, $25 Price Target
MT
ArriVent Appoints Kristine Peterson to its Board of Directors
AQ
ArriVent BioPharma, Inc. Appoints Kristine Peterson to Its Board of Directors
CI
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
AQ
ArriVent BioPharma Reports Full Year 2023 Financial Results
AQ
ArriVent BioPharma, Inc.(NasdaqGM:AVBP) added to S&P TMI Index
CI
LifeSci Capital Starts ArriVent BioPharma With Outperform Rating, $33 Price Target
MT
Citigroup Starts ArriVent BioPharma With Buy Rating, $30 Price Target
MT
Jefferies Starts ArriVent BioPharma With Buy Rating, $35 Price Target
MT
Goldman Sachs Initiates ArriVent BioPharma With Buy Rating, Price Target is $27
MT
Arrivent Biopharma Insider Bought Shares Worth $7,999,992, According to a Recent SEC Filing
MT
Arrivent Biopharma Insider Bought Shares Worth $7,999,992, According to a Recent SEC Filing
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AVBP Stock
  4. News ArriVent BioPharma, Inc.